PPP015 - Controversies about lipid-lowering therapies with Dr Rochelle Gellatly
Jane and Dan chat to Dr Rochelle Gellatly, a clinical pharmacy specialist in critical care, an Australian Advanced Practice Pharmacist in Cardiology and a Board Certified Pharmacotherapy Specialist with added qualifications in Cardiology. She is currently working in Vancouver.
We talk to Rochelle about:
- Recent changes in thinking about hyperlipidaemia, target LDLs and risk assessment
- How scores for cardiovascular risk are used in practice
- What we know (or don’t) about the optimal dose of a statin and the frequency of adverse events
Further reading:
2016 European Guidelines for the Management of Dyslipidaemias. European Heart Journal. 2016;37(39):2999-3058.
2013 American College of Cardiology/American Heart Association guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk Circulation. 2014;129(25 Suppl 2):S1-45.
Statins for Prevention of Cardiovascular Disease in Adults: Evidence Report and Systematic Review JAMA. 2016;316(19):2008-24.
European Consensus Statement: Statin-associated muscle symptoms European heart journal. 2015;36(17):1012-22.
